تقرير
أعرض في EDS

Recurrent ETV6::SYK rearrangement in myeloid malignancies confers partial susceptibility to MEK inhibition.

التفاصيل البيبلوغرافية
العنوان: Recurrent ETV6::SYK rearrangement in myeloid malignancies confers partial susceptibility to MEK inhibition.
المؤلفون: Manuelyan K; Department of Dermatology and Venereology, Medical Faculty, Trakia University and UMHAT 'Prof. Dr. St. Kirkovich', Stara Zagora, Bulgaria., Momcheva I; Department of Rheumatology Burgas, University 'Prof. Dr. Asen Zlatarov' Burgas and UMHAT Burgas, Burgas, Bulgaria., Angelova S; Laboratory of Cytogenetics and Molecular Biology, National Haematology Hospital, Sofia, Bulgaria., Nikolov K; Department of Medical Oncology, Complex Oncology Center, Burgas, Bulgaria., Shivarov V; Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria.
المصدر: British journal of haematology [Br J Haematol] 2024 Jul; Vol. 205 (1), pp. 382-386. Date of Electronic Publication: 2024 May 19.
نوع المنشور: Letter; Case Reports
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
مواضيع طبية MeSH: ETS Translocation Variant 6 Protein* , Syk Kinase*/antagonists & inhibitors , Syk Kinase*/genetics , Repressor Proteins*/genetics , Proto-Oncogene Proteins c-ets*/genetics, Humans ; Oncogene Proteins, Fusion/genetics ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Gene Rearrangement ; Male ; Female ; Middle Aged ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/drug therapy
References: Kuno Y, Abe A, Emi N, Iida M, Yamamori T, Tanimoto M, et al. An atypical myelodysplastic syndrome with t (9; 12)(q22; p12) and TEL gene rearrangement. Br J Haematol. 1999;106(2):570–571.
Lierman E, Smits S, Debackere K, André M, Michaux L, Vandenberghe P. t (9; 12)(q22; p13) ETV6:: SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia. Br J Haematol. 2023;200(5):665–668.
De Braekeleer E, Douet‐Guilbert N, Morel F, Le Bris M‐J, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res. 2012;36(8):945–961.
Biswas A, Rajesh Y, Mitra P, Mandal M. ETV6 gene aberrations in non‐haematological malignancies: a review highlighting ETV6 associated fusion genes in solid tumors. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188389.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H‐M, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228.
Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, et al. Constitutive kinase activation of the TEL‐Syk fusion gene in myelodysplastic syndrome with t (9; 12)(q22; p12). Blood. 2001;97(4):1050–1055.
Debois D, Marot L, Andre M, Dachelet C. Thalidomide as an effective treatment for adult multiple xanthogranuloma. JAAD Case Rep. 2018;4(9):896–898.
Mahmoodi M, Swami VK, Besa EC, Punnett HH. A second case of myelodysplastic syndrome with t (9; 12)(q22; p12). Cancer Genet Cytogenet. 2005;157(2):187–188.
Classen C, Minkov M, Lehrnbecher T. The non‐Langerhans cell histiocytoses (rare histiocytoses)–clinical aspects and therapeutic approaches. Klin Padiatr. 2016;228(6/7):294–306.
Kanie T, Abe A, Matsuda T, Kuno Y, Towatari M, Yamamoto T, et al. TEL‐Syk fusion constitutively activates PI3‐K/Akt, MAPK and JAK2‐independent STAT5 signal pathways. Leukemia. 2004;18(3):548–555.
Sprissler C, Belenki D, Maurer H, Aumann K, Pfeifer D, Klein C, et al. Depletion of STAT5 blocks TEL–SYK‐induced APMF‐type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J. 2014;4(8):e240.
Graham MT, Abram CL, Hu Y, Lowell CA. Expression of the TEL‐Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice. PLoS One. 2013;8(10):e77542.
Zhou M‐h, Gao L, Jing Y, Xu Y‐y, Ding Y, Wang N, et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012;91:1235–1243.
Adashek JJ, Kurzrock R. Home‐run trials for rare cancers: giving the right drug (s) to the right patients at the right time and in the right place. NPJ Precis Oncol. 2023;7(1):129.
Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, et al. Association of supporting trial evidence and reimbursement for off‐label use of cancer drugs. JAMA Netw Open. 2021;4(3):e210380.
المشرفين على المادة: 0 (ETS Translocation Variant 6 Protein)
EC 2.7.10.2 (Syk Kinase)
0 (Repressor Proteins)
0 (Proto-Oncogene Proteins c-ets)
EC 2.7.10.2 (SYK protein, human)
0 (Oncogene Proteins, Fusion)
0 (Protein Kinase Inhibitors)
تواريخ الأحداث: Date Created: 20240519 Date Completed: 20240712 Latest Revision: 20240712
رمز التحديث: 20240712
DOI: 10.1111/bjh.19549
PMID: 38763512
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2141
DOI:10.1111/bjh.19549